(Q78106881)
Statements
Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group (English)
P Hengster
M D Pescovitz
D Hyatt
scientific article published on 01 July 1999